Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse
- PMID: 9223544
Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse
Abstract
To search for use-dependent sodium channel blockers to selectively solve skeletal muscle hyperexcitability in hereditary myotonias, mexiletine (MEX; compound I) and its newly synthetized analogs, 2-(4-chloro-2-methylphenoxy)-benzenethanamine (compound II) and (-)-S-3-(2,6-dimethylphenoxy)-2-methylpropanamine (compound III), were tested on intercostal muscle fibers from the myotonic ADR mouse through use of the standard current-clamp microelectrode technique. In parallel, the effects of these compounds on the sodium channels were measured on frog muscle fibers under voltage-clamp conditions. The tonic and use-dependent blocks of peak sodium currents (I(Namax)) produced by each compound were evaluated by using a single depolarizing pulse and a pulse train at 10 Hz frequency, respectively. At 10 and 50 microM, MEX decreased the occurrence of spontaneous excitability in myotonic muscle fibers; 100 microM was required to decrease the amplitude of the action potential and the stimulus-induced firing of the membrane as well as to increase the threshold for generation of action potential. At 300 microM, MEX decreased the latency of the action potential and increased the threshold current to elicit a single action potential. MEX produced a tonic block of I(Namax) with an half-maximal concentration (IC50) of 83 microM, but the IC50 value for use-dependent block was 3-fold lower. Compound III, which differs from MEX in that it has a longer alkyl chain, similarly blocked first the spontaneous and then the stimulus-evoked excitability of myotonic muscle fibers but at 2-fold lower concentrations than MEX. Compound III was less potent than MEX in producing a tonic block of I(Namax) (IC50 = 108 microM) but was a strong use-dependent blocker with an IC50 close to 15 microM. The more lipophylic compound II irreversibly blocked both spontaneous and stimulus-evoked membrane excitability at concentrations as low as 10 microM and shortened the latency of the action potential in a concentration-dependent fashion. Compound II produced a potent tonic block of I(Namax) (IC50 = 30 microM), and its potency increased 2-fold during high-frequency stimulation. Both of the new analogs (compound II in particular), but not MEX, were less effective on the excitability parameters of striated fibers of healthy vs. ADR mice, a characteristic that increases their interest as potential antimyotonic agents.
Similar articles
-
Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back.Int J Mol Sci. 2023 Jan 3;24(1):857. doi: 10.3390/ijms24010857. Int J Mol Sci. 2023. PMID: 36614292 Free PMC article. Review.
-
Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):777-87. doi: 10.1007/pl00005118. Naunyn Schmiedebergs Arch Pharmacol. 1997. PMID: 9453464
-
Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels.Eur J Med Chem. 2000 Jan;35(1):147-56. doi: 10.1016/s0223-5234(00)00115-x. Eur J Med Chem. 2000. PMID: 10733611
-
Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers.Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;352(6):653-61. doi: 10.1007/BF00171325. Naunyn Schmiedebergs Arch Pharmacol. 1995. PMID: 9053738
-
Pharmacological therapy of non-dystrophic myotonias.Acta Myol. 2025 Mar;44(1):23-27. doi: 10.36185/2532-1900-1026. Acta Myol. 2025. PMID: 40183437 Free PMC article. Review.
Cited by
-
Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel.J Physiol. 2001 Dec 15;537(Pt 3):701-14. doi: 10.1111/j.1469-7793.2001.00701.x. J Physiol. 2001. PMID: 11744749 Free PMC article.
-
Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.Br J Pharmacol. 1999 Nov;128(6):1165-74. doi: 10.1038/sj.bjp.0702901. Br J Pharmacol. 1999. PMID: 10578128 Free PMC article.
-
Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):318-27. doi: 10.1007/s00210-002-0669-0. Epub 2003 Jan 25. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 12644906
-
Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.Br J Pharmacol. 2001 Dec;134(7):1523-31. doi: 10.1038/sj.bjp.0704366. Br J Pharmacol. 2001. PMID: 11724759 Free PMC article.
-
Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back.Int J Mol Sci. 2023 Jan 3;24(1):857. doi: 10.3390/ijms24010857. Int J Mol Sci. 2023. PMID: 36614292 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials